West Pharmaceutical Services (WST) EBT (2009 - 2026)

West Pharmaceutical Services (WST) has 18 years of EBT data on file, last reported at $180.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 62.99% year-over-year to $180.1 million; the trailing twelve-month figure through Mar 2026 stood at $670.5 million (up 17.92% YoY), and the FY2025 full-year result was $600.9 million, up 2.63% from the prior year.
• EBT climbed to $180.1 million in Q1 2026, from $161.5 million in the prior quarter.
• In the past five years, EBT ranged from a high of $227.2 million in Q2 2022 to a low of $110.5 million in Q1 2025.
• A 5-year average of $161.4 million and a median of $164.5 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT plunged 30.39% in 2024 and surged 62.99% in 2026, its largest moves.
• Tracing WST's EBT over 5 years: stood at $128.7 million in 2022, then soared by 30.69% to $168.2 million in 2023, then decreased by 1.96% to $164.9 million in 2024, then retreated by 2.06% to $161.5 million in 2025, then rose by 11.52% to $180.1 million in 2026.
• Business Quant data shows WST's EBT at $180.1 million in Q1 2026, $161.5 million in Q4 2025, and $171.9 million in Q3 2025.